Six-year-old Vensana Capital has amassed $1 billion to manage, with the closing of its latest fund, Vensana Capital III. Device investments offer few appealing exit opportunities, but with a string of successes as evidence, Vensana co-founder Justin Klein says investors who understand the landscape are benefiting from learnings that enable them to navigate it well.
— WENDY DILLER
This month at Medtech Talk, co-host Justin Klein, co-founder and managing partner at Vensana Capital, debuts in his first episode with a discussion with Douglas Kelly, former deputy center director for science and chief scientist at the Center for Devices and Radiological Health at the FDA. Kelly talks about his time at the FDA and the fundamental changes he implemented to make a helpful impact on patients, including when the pandemic was at its peak. Kelly also shares his thoughts on the value of fostering innovation and the importance of breakthrough designation, as well as how to approach the process of advocacy and get in better alignment with shared priorities with the FDA, CMS, and other stakeholders.
VENSANA CAPITAL
CAPITAL PARTNERS FOR HEALTHCARE ENTREPRENEURS®
